{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-227626","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.592652+00:00","generated_at":"2026-06-11T00:24:01.648945+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Lyra Therapeutics enters $50M at-the-market equity offering with Cantor Fitzgerald","bullets":["Enters Controlled Equity Offering Sales Agreement to sell up to $50.0M of common stock through Cantor Fitzgerald.","Shares sold in at-the-market offerings; Cantor receives 3.0% commission on gross proceeds.","Company has no obligation to sell any shares and may suspend or terminate offering at any time.","Offering registered under existing S-3 shelf; prospectus supplement filed September 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-227626","json":"https://secwatch.observer/filing/0001193125-23-227626.json","markdown":"https://secwatch.observer/filing/0001193125-23-227626.md","text":"https://secwatch.observer/filing/0001193125-23-227626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/0001193125-23-227626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/d498636d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T00:24:01.648945+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a21e845c26106641f6cfc03b5c1d6694a93ffe07","claim":"Lyra Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at $50.0 million (effective 2023-09-01).","evidence_excerpt":"On September 1, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), for aggregate gross proceeds of up to $50.0 million (the “Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/0001193125-23-227626-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Cantor Fitzgerald & Co."},{"label":"Value","value":"$50.0 million"},{"label":"Effective","value":"2023-09-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}